Only 2 years after the introduction of methicillin, the first methicillin resistant S. aureus (MRSA) was isolated in a British hospital. 9, 10 From there, MRSA spread across borders to cause significant hospital and community infections worldwide. Today, the terms methicillin sensitive S. aureus (MSSA) or oxacillin sensitive S. aureus (OSSA) are used interchangeably. These differentiate isolates susceptible to PRPs from their resistant counterparts (MRSA, ORSA).
Methicillin resistance is attributed to the presence of an alternative penicillin binding protein (PBP2a or PBP2′) that is encoded by a gene called mecA. 11 MSSA is transformed into MRSA upon acquisition of mecA. 12, 13 The mecA gene is part of a mobile genetic island called Staphylococcal Cassette Chromosome mec (SCCmec).
Excision and integration of an SCCmec into the host's genetic material are mediated by cassette chromosome recombinases (Ccr). 14 The type of SCCmec is defined by the combination of mecA and ccr it contains. 13 So far, 12 types of SCCmec elements have been described. 12, 14 The prevalence of each type varies geographically. Most hospitalassociated MRSA (HA-MRSA) strains carry larger SCCmec (types I, II, or III). Community-associated MRSA (CA-MRSA) strains carry the smaller SCCmec (types IV or V). 15, 16 It is thought that the spread of CA-MRSA strains is facilitated by the easier translocation of their small SCCmec complexes. 17 In 2011, mecC carrying MRSA strains affecting mostly animals have been described, often termed life-stock associated MRSA (LA-MRSA). Although mecC MRSA colonization and infection has been described in humans, it occurred with very low prevalence; however, mecC adds to difficulties in laboratory detection given variable methicillin-resistance. [18] [19] [20] PBP2a has low affinity to β-lactams compared to other PBPs.
Therefore, they enable MRSA to continue cell wall synthesis in the presence of β-lactams.
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3 | A mecA NEGATIVE MRSA AND LABORATORY METHODS
Borderline oxacillin-resistant S. aureus (BORSA), not containing the mecA element, has been described in the literature. The initial definition in 1988 included S. aureus strains with oxacillin MIC < 2 μg/mL and full susceptibility to other PRPs (methicillin, nafcillin, and cloxacillin). 22 However, in 2009, Skinner et al showed that certain BORSA strains could have an oxacillin minimal inhibitory concentration (MIC) up to 4-16 μg/mL with dose dependent susceptibility to other PRPs. 23 The mechanism of this borderline resistance is not completely defined and likely includes multiple factors: (a) β-lactamase hypersecretion that rapidly hydrolyzes penicillin and partially or slowly hydrolyzes the PRPs 24 ; (b) plasmidmediated, inducible methicillinase 25 ; and/or (c) modifications in the penicillin binding protein genes. 26 Addition of a β-lactamase inhibitor to β-lactamase hypersecreting BORSA strains should restore their oxacillin susceptibility. 23, 27 Thus strains that do not follow this pattern have also been referred to as modified S. aureus (MODSA) to distinguish them from the lactamase hyper-producing BORSA. 28 In a single CF center study, Leahy et al showed that 18/34 of S. aureus isolates with methicillin resistance were BORSA. 27 Patient outcomes did not differ by BORSA versus MRSA.
The distinction between mecA positive MRSA and BORSA may be relevant to diagnostics, antibiotic selection, and diagnostics. Currently, the presence of mecA is the main genetic determinant of methicillin resistance that differentiates between MRSA and BORSA/MODSA.
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In clinical microbiology laboratories, different methods are being used to determine bacterial sensitivities. Some methods employed to test methicillin susceptibility include disc diffusion, MIC determination by e-test, PBP2a latex agglutination, and molecular methods like PCR and genetic sequencing. 29, 30 Several molecular methods for determination of methicillin-resistance rely on the identification of the mecA element, but these methods would fail to identify BORSA.
Antibiotics used in disc diffusion and e-tests include oxacillin, methicillin, and cefoxitin. 31 Culture based methods for determination of MRSA using commercial chromogenic media showed lower specificity but still high sensitivity when BORSA isolates were tested. 32 Since early identification of methicillin resistance is relevant to treatment and infection control measures lower specificity still meets those goals. to determine in epidemiologic studies given differences in underlying disease and treatment. BORSA. 27 This observation suggests that patients with CF acquire BORSA due to antibiotic pressure rather than interpersonal transmission as in the case of MRSA.
A sub-set of MRSA strains produces PVL, which was first described in 1932. 60 Twenty-seven years later, Woodin was the first to purify PVL and identify its two components: LukS-PV and LukF-PV. 61 Panton-Valentine leukocidin induces necrosis of neutrophils, monocytes, and macrophages by binding to specific membrane receptors and forming a membrane perforating octamer. 62 It has been suggested that the type of SCV isolated from patients depend on previous antibiotic exposures. 67 Long term antibiotic therapy, predisposes to SCVs. Table 1 summarizes the association between SCV type and specific antibiotics.
An accurate assessment of the SVC prevalence in CF is challenging given the difficulty of growing and detecting SCV S. aureus in diagnostic laboratories. Small-colony variant S. aureus was found in 8.1-24% of patients with CF. [70] [71] [72] [73] These studies also showed an association between presence of SCV S. aureus and more rapid pulmonary decline.
Small-colony variant formation also occurs in MRSA but has only been reported in few cases in CF 74, 75 and non-CF. 76, 77 Other patterns of adaptation during chronic infection are growth under anaerobic conditions, 78 biofilm formation, 79 and development of so called persister isolates. 80 None of these growth modes are specific to MRSA, yet all are associated with decreased metabolic activity and slower growth, making them more difficult to treat. For infants, birth by C-section is one reported factor associated with higher S. aureus carriage. This has not been studied specifically for CF.
A study comparing naso-pharyngeal microbiome in CF and non-CF infants during the first 6 months of life, showed differences in microbiome emerge within the first few months, where S. aureus was one of the taxa more dominant in CF. 81 Jointly these data indicate that early MRSA eradication is possible but duration and exact treatment regimen need to be defined.
The most frequently used antibiotics in non-randomized trials include fusidic acid (not licensed in the United States) and TMP-SMX mostly in combination with rifampin. More aggressive approaches using either a step-wise protocol to include an IV antibiotic if oral fusidic acid failed 99 or an a priori course of 3-week IV antibiotics followed by 6 weeks dual oral antibiotics based on susceptibility and inhaled vancomycin 100 have also been reported.
Two case series also reported eradication success of chronic MRSA infection using a 6 month therapy with fusidic acid and rifampin. 101, 102 A more recent trial in the United States compared dual antibiotics with reference to dosing is provided in Table 3 .
Fluoroquinolones are not recommended for use for MRSA due to high rates of resistance in patients with CF. Further, fluoroquinolones can induce high level oxacillin resistance with cross-resistance to other antibiotic classes. 107 Either constitutive or inducible resistance to clindamycin is present in many MRSA strains isolated from people with CF making this an unlikely option for use. Antibiotic resistance with prolonged or repeated use can occur with any of the antibiotics listed in 
| Novel antibiotics and therapeutic approaches
Most novel antibiotics have been evaluated for complicated skin and soft tissue infections (cSSTI) and are derivatives of existing antibiotics (eg, new generation glycopeptides and glycolipopeptides) as summarized in Table 4 . Therefore, the usefulness of such antibiotics for lung infections and possible need for dose modifications in CF are presently unknown.
Inhaled antibiotics provide high doses of antibiotics to the airways without systemic side effects. After deposition in the airways antibiotic solubility and diffusion through the mucus layer is required to achieve effective antibiotic concentrations at the site of infection, reviewed in Bos et al. 121 Challenges with inhaled antibiotics are the heterogeneous lung disease in CF, which may cause unequal deposition within the lungs with potential for decreased delivery to the most obstructed Additional approaches may include coupling antimicrobials to nanoparticles, 123, 124 phage therapy, 125, 126 or antimicrobial peptides. 127 Such approaches may also prove useful for other pathogens given their less selective mechanisms. 128 As shown in Figure 1, 
